High Court Refuses To Hear Authorized Generics Suit

Law360, New York (June 25, 2007, 12:00 AM EDT) -- The U.S. Supreme Court on Monday refused to hear the tamoxifen citrate antitrust lawsuit, meaning it will not weigh in on the legal issues surrounding authorized generics.

The move to deny cert was a victory for Barr Pharmaceuticals Inc., which had argued that a patent litigation settlement agreement it reached with AstraZeneca PLC in 1993 did not violate antitrust or consumer protection statutes.

“We have always believed that our patent challenge settlement related to tamoxifen citrate was pro-consumer and pro-competitive, and this has now been definitively...
To view the full article, register now.